profit from every $100 of sales.
$0$100
20/20 Biolabs
$0.20+1.88% today
-99.2% since Feb 19, 26
1-year low $0.191-year high $23.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What 20/20 Biolabs sold, what it kept, and what it did with the cash.
Sales went from $1.42 million in 2023 to $2.05 million in 2025, with -$3.74 million of profit last year.
SalesProfit
20/20 Biolabs vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| 20/20 Biolabs | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads 20/20 Biolabs's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 1 | 2 | 2 | |
| 0 | 0 | 1 | |
| -6 | -6 | -3 | |
| -6 | -5 | -4 | |
| -6 | -6 | -4 | |
| -0.62 | -0.54 | -0.36 | |
| 7.7% | 20.6% | 29.6% | |
| -446.6% | -323.1% | -162.9% | |
| -448.7% | -316.8% | -182.8% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 6 | 4 | 4 |
| Cash | 4 | 2 | 1 |
| Total debt | 1 | 1 | 1 |
| Total liabilities | 2 | 2 | 4 |
| 4 | 2 | -0 | |
| 10 | 10 | 10 | |
| -91.1% | -186.6% | -211.3% | |
| -149.1% | -368.8% | 19,447.7% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -4 | -3 | -2 | |
| 0 | – | – | |
| -5 | -3 | -2 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 1 | 2 | 1 |
Valuation
- –
- –
- –
- 2.6×
- 1.3×
- –
- –
- -71.8%
- -139.9%
- 0.0%
Profitability
- 29.6%
- -162.9%
- -182.8%
- -263.2%
- -102.2%
- -107.5%
- 111.7%
- -72.3%
- -108.2%
- 55.9%
Growth
- +19.8%
- –
- −73,770.0%
- –
- –
Financial health
- –
- 0.24
- 10.7%
- 14.7×
- 1.82
- 1.78
- 0.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 871
Top 29%of 868
Bottom 1%of 985
News
20/20 Biolabs Q2 GAAP EPS of -$0.26, revenue of $0.73MSeeking Alpha · Aug 17, 2026The newest story we have is from Aug 17, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
36No pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
21No pass
Terry Smith
26No pass
Questions about 20/20 Biolabs
Is 20/20 Biolabs a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the 20/20 Biolabs AI analysis
What does 20/20 Biolabs do?
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. It is in Medical - Devices.
Does 20/20 Biolabs pay a dividend?
No. 20/20 Biolabs does not pay a dividend at the moment.
Is 20/20 Biolabs stock halal?
No. 20/20 Biolabs does not pass our halal screen: its debt is 51% of its market value, at or above the 33% limit. How we check
Who are 20/20 Biolabs's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with 20/20 Biolabs's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.